Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ranbaxy to Join Daiichi Sankyo to Market Olmesartan in India
January 26, 2009
- Novartis to Start Global PIII Trial of Everolimus for Stomach Cancer Based on POC Established in Japan
January 26, 2009
- Taisho Ties Up with GSK to Commercialize Xenical in Japan
January 26, 2009
- Biosimilars Are Likely to Be Developed by Research-Driven Companies in Japan: Ihoken
January 26, 2009
- Korosho to Draw Conclusion on Drug Pricing System Reform in 2009: Mr Kinoshita
January 26, 2009
- Inhibition of BDNF by Stress Hormones Shown by NCNP/NIN Research Team
January 26, 2009
- Diovan Remains Number One: Rep Track Survey
January 26, 2009
- Jansen: Intelence for HIV-1 Infection
January 26, 2009
- BUSINESS NEWS IN BRIEF
January 26, 2009
- Sato Enters the Field of Diagnostic Agents
January 26, 2009
- Nichi-Iko Aims at Entering Global Top-10 Club in 2012: President Tamura
January 26, 2009
- 3,030 Reports on Device Malfunctions Received in 1st Half of FY2008
January 26, 2009
- JGA to Demand Fixed Sum Price Adjustment Range for Low-Priced Generics
January 26, 2009
- Kaken: Hand-Sized Seprafilm
January 26, 2009
- Cravit to See NHI Price Listing for 41 Generics from 32 Companies
January 26, 2009
- Endometrial Ablation Using Microwaves Approved as Advanced Therapy
January 26, 2009
- Generics Account for 18% of Drug Cost at a Yokohama Hospital
January 26, 2009
- SELF-MEDICATION NEWS IN BRIEF
January 26, 2009
- Review of Febuxostat by FDA to Be Extended
January 26, 2009
- Revised Version of Hypertension Treatment GL Issued
January 26, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…